BiotechTube
Fibronostics

Fibronostics

New Orleans, United States· Est.
fibronostics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $7M

Overview

Fibronostics is a commercial-stage diagnostics company providing AI-powered, blood-based tests for metabolic liver disease. Its core technology, LIVERFASt™, analyzes 10 common biomarkers and patient data to generate a score that correlates with biopsy results for fibrosis, inflammation, and fat content. The company operates a CAP/CLIA certified lab, targets physicians, health systems, and pharma companies, and positions its test as a superior, non-invasive alternative to tools like FIB-4 and FibroScan. Founded in 2015 and headquartered in New Orleans, it is a private company in the early revenue stage.

Metabolic Liver DiseaseHepatology

Technology Platform

AI-powered software algorithm that analyzes 10 standard blood biomarkers and patient anthropometrics to generate scores for liver fibrosis, necroinflammatory activity, and steatosis (fat content), functioning as a non-invasive diagnostic tool.

Funding History

2
Total raised:$7M
Series A$5M
Seed$2M

Opportunities

The global MASLD/MASH epidemic and recent approval of the first MASH drugs create a massive, growing need for non-invasive diagnostic and monitoring tools.
Fibronostics can capitalize by targeting population screening in primary care, detailed staging in hepatology, and serving as a biomarker for pharmaceutical clinical trials.

Risk Factors

The company faces intense competition from established non-invasive tests (e.g., FibroScan, FIB-4, ELF test) and must secure favorable insurance reimbursement to achieve widespread adoption.
Its commercial success is heavily dependent on continued clinical validation and inclusion in major professional treatment guidelines.

Competitive Landscape

Fibronostics competes in the crowded non-invasive liver disease diagnostics market. Key competitors include Echosens (FibroScan - imaging), bioinformatics blood tests like the Enhanced Liver Fibrosis (ELF) test offered by LabCorp/Siemens, and simple biomarker ratios like FIB-4. Its differentiation is a single, comprehensive blood test for fibrosis, activity, and steatosis.

More companies in Diagnostics & Precision Medicine →More companies in United States →